Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
323 participants in 5 patient groups, including a placebo group
There are currently no registered sites for this trial.
Start date
Sep 28, 2016 • 8 years ago
End date
Nov 12, 2020 • 4 years ago
Results posted
ViewFeb 18, 2022 • 2 years ago
Today
Jan 23, 2025
Lead Sponsor
Collaborating Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal